Noom Offers Free GLP-1 Support to Help Users Keep Weight Off and Preserve Muscle
Noom's free GLP-1 Companion program targets muscle loss, side effects, and habit formation to extend results beyond medication.
Summary
Noom has launched a free digital support program for anyone taking GLP-1 weight-loss medications like Ozempic or Wegovy. The platform addresses one of the biggest gaps in GLP-1 therapy: what happens after the weight comes off. Features include personalized protein targets, resistance training guidance, medication tracking, and side-effect management tools. The move reflects growing concern in obesity medicine that rapid weight loss on GLP-1s can erode lean muscle mass, which matters deeply for long-term metabolic health and physical function — especially in older adults. Noom's CEO acknowledged the company is still building its evidence base for body composition outcomes, but the direction is clear: behavioral and nutritional scaffolding is becoming as important as the drug itself.
Detailed Summary
GLP-1 medications have transformed obesity treatment, but a critical question is emerging in both clinical and longevity circles: can the results last? Millions of patients are losing significant weight, yet real-world data suggest many discontinue treatment within the first year — and weight regain is common. Noom's new free GLP-1 Companion platform is designed to address exactly this gap, offering behavioral and nutritional support alongside pharmacotherapy at no cost to any GLP-1 user.
The platform focuses on several friction points that undermine long-term outcomes: insufficient protein intake, gastrointestinal side effects, and loss of lean muscle mass during rapid weight loss. Users receive personalized protein targets, resistance exercise programming, medication tracking tools, and educational content tailored to their treatment phase. The emphasis on muscle preservation is deliberate and scientifically grounded.
For longevity practitioners, the muscle-loss issue carries particular weight. Studies consistently show that lean mass is protective against metabolic decline, frailty, and mortality in aging adults. When GLP-1-driven weight loss erodes muscle alongside fat, the net benefit to healthspan may be diminished — especially if patients later regain fat without recovering muscle. Noom CEO Geoff Cook cited this as a central design concern, noting that post-discontinuation weight regain may further worsen body composition if lean mass was not preserved during treatment.
The broader implication is structural. Healthcare systems were not designed to deliver intensive lifestyle coaching at the scale GLP-1 prescribing now demands. Digital platforms are stepping into that gap not as luxury add-ons but as functional necessities. Whether they can deliver durable outcomes at population scale remains unproven.
Caveats are real: Noom has not yet published robust long-term body composition data from this program, and the platform's efficacy relative to in-person coaching or clinical supervision is unknown. Still, the shift in framing — from weight loss to healthspan maintenance — signals a maturing conversation in obesity medicine.
Key Findings
- Noom's free GLP-1 Companion program is now available to all GLP-1 users regardless of prescriber.
- Program targets muscle preservation via personalized protein targets and resistance training guidance.
- Many GLP-1 patients discontinue within one year, making behavioral scaffolding critical for lasting results.
- Lean mass loss during rapid GLP-1-driven weight loss poses real risks to metabolic health and physical function.
- Noom acknowledges its body composition outcome evidence base is still being built.
Methodology
This is a news report from Longevity.Technology covering a product launch by Noom, including a CEO interview. It is not a peer-reviewed study; evidence basis is largely expert opinion and cited real-world discontinuation trends rather than clinical trial data.
Study Limitations
No peer-reviewed clinical trial data on Noom's GLP-1 Companion outcomes are cited; long-term efficacy for body composition is unproven. The article is partly promotional in nature and should be interpreted alongside independent clinical evidence on behavioral interventions for GLP-1 users.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: